Ryan Bitton, PharmD, MBA

Articles

Improving Access and Uptake of HIV PrEP

February 22, 2022

Sean E. Bland, JD; Frank J. Palella, MD; and Carl Schmid explore organizational opportunities to improve access to HIV PrEP therapy and population health management strategies to improve PrEP uptake.

COVID-19’s Effect on Access to HIV PrEP Therapy

February 22, 2022

Carl Schmid discusses how the COVID-19 pandemic has amplified health care disparities and accessing HIV PrEP, and Frank J. Palella, MD, comments on the role of telehealth in improving access to PrEP.

Using Real-World Evidence for HIV PrEP Policies

February 15, 2022

Ryan Bitton, PharmD, MBA, provides a payer perspective on the importance of creating future health policies for HIV PrEP agents using real-world evidence and considering the total cost of care for patients.

Unmet Needs for USPSTF Guidelines for HIV PrEP

February 15, 2022

Ryan Bitton, PharmD, MBA; Sean E. Bland, JD; Frank J. Palella, MD; and Carl Schmid comment on challenges in the implementation of USPSTF guidelines for HIV PrEP as well as existing unknowns with the guidance.

USPSTF Guidelines: Approaching Optimal Therapy for HIV PrEP

February 08, 2022

Frank J. Palella, MD, shares a provider perspective for steps to take in accordance with USPSTF guidelines for HIV PrEP to get patients appropriate medications, and Ryan Bitton, PharmD, MBA, shares a provider prospective on supporting expedited prior authorizations.

USPSTF Guidelines for HIV PrEP: Using Medical Management Techniques

February 08, 2022

Sean E. Bland, JD, provides insight for when a health plan or issuer may use reasonable medical-management techniques, in accordance with USPSTF guidelines for HIV PrEP, and Ryan Bitton, PharmD, MBA, shares a payer perspective on utilization-management policies regarding PrEP.